Why Precision Biosciences Inc (DTIL) Stock Could See Much Higher Prices Ahead

Precision Biosciences Inc (NASDAQ: DTIL) is 2.77% higher on its value in year-to-date trading and has touched a low of $0.28 and a high of $1.29 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The DTIL stock was last observed hovering at around $0.38 in the last trading session, with the day’s loss setting it 0.0%.

Currently trading at $0.38, the stock is -2.03% and -2.35% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.5 million and changing -2.32% at the moment leaves the stock -24.72% off its SMA200. DTIL registered -66.81% loss for a year compared to 6-month loss of -29.89%. The firm has a 50-day simple moving average (SMA 50) of -$0.99 and a 200-day simple moving average (SMA200) of $0.68.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a -12.15% gain in the last 1 month and extending the period to 3 months gives it a -4.80%, and is -1.52% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.83% over the week and 6.01% over the month.

Profit margin for the company is -156.76%. Distance from 52-week low is 36.40% and -70.91% from its 52-week high. The company has generated returns on investments over the last 12 months (-282.02%).

Precision Biosciences Inc quarterly earnings per share for the current quarter are estimated at -$0.07 with sales reaching $12.48M over the same period.The EPS is expected to grow by 60.47% this year, but quarterly earnings will post 112.40% year-over-year. Quarterly sales are estimated to grow 17.80% in year-over-year returns.

Precision Biosciences Inc (DTIL) Top Institutional Holders

90 institutions hold shares in Precision Biosciences Inc (DTIL), with institutional investors hold 40.81% of the company’s shares. The shares outstanding are 110.96M, and float is at 96.53M with Short Float at 1.71%. Institutions hold 35.00% of the Float.

The top institutional shareholder in the company is Great Point Partners LLC with over 7.47 million shares valued at $3.93 million. The investor’s holdings represent 6.49% of the DTIL Shares outstanding. As of Jun 29, 2023, the second largest holder is Capital World Investors with 6.72 million shares valued at $3.53 million to account for 5.84% of the shares outstanding. The other top investors are Vanguard Group Inc which holds 4.72 million shares representing 4.10% and valued at over $2.48 million, while Acadian Asset Management. LLC holds 2.53% of the shares totaling 2.91 million with a market value of $1.53 million.

Precision Biosciences Inc (DTIL) Insider Activity

A total of 10 insider transactions have happened at Precision Biosciences Inc (DTIL) in the last six months, with sales accounting for 2 and purchases happening 8 times. The most recent transaction is an insider sale by SMITH J. JEFFERSON,the company’sChief Research Officer. SEC filings show that SMITH J. JEFFERSON sold 28,000 shares of the company’s common stock on Jan 23 at a price of $0.37 per share for a total of $10360.0. Following the sale, the insider now owns 1.99 million shares.

Precision Biosciences Inc disclosed in a document filed with the SEC on Jan 22 that Amoroso Michael (President and CEO) sold a total of 137,390 shares of the company’s common stock. The trade occurred on Jan 22 and was made at $0.36 per share for $49460.0. Following the transaction, the insider now directly holds 0.36 million shares of the DTIL stock.

Still, SEC filings show that on Jan 22, List Alan (Chief Medical Officer) disposed off 21,526 shares at an average price of $0.36 for $7749.0. The insider now directly holds 94,982 shares of Precision Biosciences Inc (DTIL).

Precision Biosciences Inc (DTIL): Who are the competitors?

The company’s main competitors (and peers) include Bristol Myers Squibb Co. (BMY) that is trading -32.01% down over the past 12 months. Alnylam Pharmaceuticals Inc. (ALNY) that is -23.84% lower over the same period.